Gosset
Book a demo

European Lung Cancer Congress 2026: key results and trends

What the 489 abstracts at European Lung Cancer Congress 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.

abstracts
489
drug-linked abstracts
246
companies
58
from Phase 3 studies
37

Drug-linked abstracts by phase

  • Phase 1 14
  • Phase 1/2 12
  • Phase 2 44
  • Phase 2/3 3
  • Phase 3 37
  • Phase 4 2

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Non-small cell lung cancer (NSCLC)AstraZeneca

    osimertinib

    Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)

    Osi + CTx significantly improved PFS versus osi (HR 0.44; 95% CI 0.32, 0.61; p<0.001; 59% maturity).

    Read the abstract (opens in a new tab)

  2. Phase 3Non-small cell lung cancer (NSCLC)Jiangsu Aosaikang Pharmaceutical

    limertinib

    First-line limertinib versus gefitinib in EGFR-mutated advanced NSCLC: Updated overall survival results from a randomized, double-blind, phase III trial

    The median OS was 43.3 months (95% CI: 35.9–48.2) with limertinib versus 34.5 months (95% CI: 28.7–39.3) with gefitinib (HR 0.78; 95% CI: 0.58–1.05; p=0.1013).

    Read the abstract (opens in a new tab)

  3. Phase 3Pulmonary squamous cell carcinomaBioNTech

    gotistobart

    Anti-tumor activity of gotistobart compared to docetaxel in patients with metastatic squamous non-small cell lung cancer (sqNSCLC) progressing on PD-(L)1 inhibitors: Stage 1 PRESERVE-003 phase III trial

    Median PFS was similar (2.4 m vs 2.6 m), but the 12-m PFS rate was 25% for gotistobart and 0% for docetaxel, with a HR of 0.69 (95% CI, 0.42, 1.13) favoring gotistobart.

    Read the abstract (opens in a new tab)

  4. Phase 3Small cell lung cancer (SCLC)Jiangsu HengRui Medicine Co., Ltd.

    adebrelimab

    Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): 5-year update of the phase III CAPSTONE-1 study

    The OS benefit with adebrelimab + chemo vs placebo + chemo was maintained (HR 0.73 [95% CI 0.60–0.89], 1-sided nominal p=0.0008).

    Read the abstract (opens in a new tab)

  5. Phase 3Non-small cell lung cancer (NSCLC)Akeso

    ivonescimab

    Health-related quality of life in patients previously treated with an EGFR-TKI from HARMONi: A phase III trial of ivonescimab vs placebo plus chemotherapy

    TTD in GHS/QoL was also comparable in both arms, with a longer TTD for IVO + CT than PBO + CT, median 7.0 mos vs 6.5 mos (HR 0.90, 95% CI 0.73-1.12).

    Read the abstract (opens in a new tab)

  6. Phase 3Small cell lung cancer (SCLC)AstraZeneca

    durvalumab

    Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

    TFST was prolonged with D vs P (HR 0.72 [95% CI 0.58–0.90]; median [95% CI] 26.6 [19.2–37.3] vs 15.3 [12.0–19.9] mo), as was PFS2 (HR 0.66 [95% CI 0.49–0.88]; median [95% CI] not reached (NR) [NR–NR] vs 37.6 [25.3–NR] mo).

    Read the abstract (opens in a new tab)

  7. Phase 3Small cell lung cancer (SCLC)

    lurbinectedin

    IMforte: Subsequent treatment (Tx) following first-line maintenance (1Lm) with lurbinectedin (lurbi) + atezolizumab (atezo) or atezo in extensive stage small cell lung cancer (ES-SCLC)

    The OS benefit favouring lurbi + atezo over atezo was maintained after adjusting for survival bias introduced by 2L lurbi (HR, 0.68 [95% CI: 0.52, 0.90]).

    Read the abstract (opens in a new tab)

  8. Phase 3Non-small cell lung cancer (NSCLC)Merck

    pembrolizumab

    Exploratory analysis of participants without pathological complete response (pCR) in the KEYNOTE-671 study of perioperative pembrolizumab (pembro) in early-stage NSCLC after 5 years of follow-up

    The HR for EFS was 0.69 (95% CI, 0.57–0.83), favoring the pembro vs placebo arm.

    Read the abstract (opens in a new tab)

  9. Phase 3Non-small cell lung cancer (NSCLC)Regeneron Pharmaceuticals

    cemiplimab

    Impact of genomic alterations on clinical outcomes with first-line cemiplimab + chemotherapy for advanced NSCLC: An analysis from EMPOWER-Lung 3

    In STK11 wt pts, cemi+chemo showed OS benefit vs chemo (median OS 18.1 vs 7.6 months [mo]; HR=0.49, 95% CI: 0.31–0.78).

    Read the abstract (opens in a new tab)

  10. Phase 2Non-small cell lung cancer (NSCLC)

    UV1

    UV1 vaccine with standard of care PD-1 checkpoint inhibitor as first-line treatment for non-small cell lung cancer (NSCLC): A randomized phase II trial

    TTR and ORR were 2 mo and 53.3 % (UV1+SoC) vs 3 mo and 46.7 % (SoC) (HR=0.96, 95% CI: 0.35-2,67), and median DoR was 17 mo (UV1+SoC) vs 11 mo (SoC) (HR=0.79; 95% CI: 0.25-2.46).

    Read the abstract (opens in a new tab)

  11. Phase 2Small cell lung cancer (SCLC)

    serplulimab

    Serplulimab consolidation after concurrent hypofractionated chemoradiotherapy for limited-stage small cell lung cancer

    The median PFS was 27.5 months (95% CI: 15.7-NR) since initiation of serplulimab, with 1- and 2-year PFS rates of 63.6% (95% CI: 52.1-77.7%) and 54.0% (95% CI: 42.2-69.1%), respectively.

    Read the abstract (opens in a new tab)

  12. Phase 2Small cell lung cancer (SCLC)BioNTech

    pumitamig

    Phase II study of first-line pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy for extensive-stage small cell lung cancer (ES-SCLC): Updated efficacy and safety results

    Four pts (8%) discontinued treatment due to pumitamig-related TEAEs.

    Read the abstract (opens in a new tab)

Small molecules were the most frequent modality (55% of drug-linked abstracts). PDCD1 was the most frequent target (22%). Non-small cell lung cancer (NSCLC) was the most frequent disease (78%).

What the abstracts covered

Share of the 246 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Antibody-drug conjugates9%22 drug-linked abstracts
  • Bispecific antibodies11%28 drug-linked abstracts

Top targets

  1. PDCD15422%
  2. EGFR4719%
  3. CD2743514%
  4. VEGFA125%
  5. ALK114%
  6. ERBB2114%
  7. MET104%
  8. ROS194%
  9. KRASG12C83%
  10. RET83%

Top modalities

  1. Small molecules13555%
  2. Monoclonal antibodies10041%
  3. Bispecific antibodies2811%
  4. Antibody-drug conjugates229%
  5. Vaccines31%
  6. Cell therapies21%
  7. Peptides21%
  8. Radiopharmaceuticals21%

Top diseases

  1. Non-small cell lung cancer (NSCLC)19278%
  2. Small cell lung cancer (SCLC)3313%
  3. Bronchial carcinoma83%
  4. Non-small cell lung cancer adenocarcinoma (NSCLC)73%
  5. Pulmonary squamous cell carcinoma62%
  6. Brain metastases42%
  7. Non-small cell lung cancer (NS-NSCLC)42%
  8. Pleural mesothelioma42%
  9. Carcinomatous Meningitis (CM)21%
  10. Large cell neuroendocrine carcinoma (LCNEC)21%

Most active companies

  1. AstraZeneca3615%
  2. Bristol Myers Squibb229%
  3. Merck187%
  4. Pfizer156%
  5. Genentech114%
  6. Hansoh Pharmaceutical Group114%
  7. Daiichi Sankyo104%
  8. Eli Lilly73%
  9. BioNTech62%
  10. Akeso42%

Explore every ELCC 2026 result in Gosset

All 246 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Get full accessExplore the results in Gosset

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call